MYCN and neuroblastoma: Long‐term survival of high‐risk neuroblastoma patients (metastatic disease over 1 year of age or MYCN amplified disease) currently remains less than 50%, with those that survive often suffering long‐term side effects as a consequence of high‐dose intensive multimodal treatment.1 The identification of novel therapies that improve survival and reduce toxicity is urgently needed.